Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.
about
Defining the clinical course of multiple sclerosis: the 2013 revisions.Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic reviewImmunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysisRecombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosisReview of interferon beta-1b in the treatment of early and relapsing multiple sclerosisOptical coherence tomography: a window into the mechanisms of multiple sclerosisDisease-modifying treatments for multiple sclerosis - a review of approved medicationsOptimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosisTreatment strategies for multiple sclerosis: When to start, when to change, when to stop?Relating relapse and T2 lesion changes to disability progression in multiple sclerosis: a systematic literature review and regression analysisProfile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosisReview of the pharmacoeconomics of early treatment of multiple sclerosis using interferon betaPharmacological Approaches to Delaying Disability Progression in Patients with Multiple SclerosisRisk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple SclerosisThe mechanism of action of interferon-β in relapsing multiple sclerosisTreatment of cognitive impairment in patients with multiple sclerosisDevelopment of oral immunomodulatory agents in the management of multiple sclerosisEstablishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MSCountry, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndromeRisk Factors for Poor Adherence to Betaferon® Treatment in Patients with Relapsing-Remitting Multiple Sclerosis or Clinically Isolated SyndromeCurrent and emerging therapies in multiple sclerosis: a systematic reviewDifferential diagnosis of suspected multiple sclerosis: a consensus approachTreatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.Pharmacokinetic considerations in the treatment of multiple sclerosis with interferon-β.Survey of US Patients with Multiple Sclerosis: Comparison of the New Electronic Interferon Beta-1b Autoinjector (BETACONNECT™) With Mechanical AutoinjectorsThe CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: Design and baseline characteristics.Analysis of NAMCS data for multiple sclerosis, 1998-2004.Subtraction MR images in a multiple sclerosis multicenter clinical trial setting.MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome.Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode.Outcome measures in relapsing-remitting multiple sclerosis: capturing disability and disease progression in clinical trials.The diagnosis of multiple sclerosis and the clinical subtypes.Disease-modifying agents in multiple sclerosis.New developments in the treatment of optic neuritis.Alternative statistical methods for estimating efficacy of interferon beta-1b for multiple sclerosis clinical trials.The radiologically isolated syndrome: look (again) before you treat.Drug therapy for multiple sclerosis.Subcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis.Efficacy and safety of subcutaneous interferon-β-1a in patients with a first demyelinating event and early multiple sclerosis.Comparison of multifocal visual evoked potential, standard automated perimetry and optical coherence tomography in assessing visual pathway in multiple sclerosis patients.
P2860
Q22241654-FD1C9E60-F10D-47FC-AF8E-5B770670BC16Q22241795-016A04D3-4D32-4493-BCF3-2A62B13A1DF4Q24202108-E02C0E5C-08E7-49F2-B7FB-7A3533442DEFQ24243043-39E0FB0E-9112-44E4-A1A5-118EE8C9DEACQ24652353-62DA590A-F1B1-4686-B0DE-E5CF6C3676CDQ24655514-A6D7048F-3C41-4247-8405-668AED60BABBQ26777329-DC6FF816-8601-4B5E-AF20-C811487CC0DBQ26777686-9B8C5D50-8974-4819-A5F4-36E3CCC1A006Q26798434-DA0BF6B1-8059-4F08-8BD8-6CFF1A003E6AQ26828463-D1F083F0-CF30-46F7-B83E-192119E3ACD4Q26852672-22162346-F743-49A0-8C3A-69982EB255EDQ26864418-BB0A3784-6BA8-4211-9C64-F091D892379EQ27000269-013DA0EF-F2CF-4E9E-8DD8-201A2610097DQ28087414-6F57FBA7-D3B8-437E-95F9-8F6E5CBFEF4AQ28239752-045A08FB-0F1D-4773-908B-81898581E898Q28272736-62A5DE7D-7983-4CB3-A45C-263DE30102A3Q28388704-ED79C0D4-A662-46E2-BF2F-B5BF9CDE5C6DQ28478190-9A7BF501-9885-44C2-B22D-6E2A742AC7A6Q28480907-DA3EDC81-9711-4A0A-8458-C8E14D50B1D6Q28554434-AA3D1209-42D9-4358-B661-B598A871A20DQ29010983-65796133-66D7-4DDB-B352-C40B4DBF3347Q29039412-FFA02FA5-0397-4D9A-BA05-C5A0EFBBBDE8Q30234672-6EBDDD7C-512E-4A03-8D60-7F75F55F3170Q30379738-F451A3EA-0039-4609-AF0D-1382D75ABE96Q30830291-19B20559-6C1C-4AA9-8465-51BE3DD0521DQ30932853-85FA0DA0-1837-4FDE-A03A-1580EC652728Q31108210-0BE453A3-DA35-4090-B32A-3D72352D2661Q33387539-1C52BB95-2BC6-47FC-8367-FA1E35144E01Q33449002-57F3EDB2-F1AE-4A65-89FF-D37A2CD4001CQ33500910-D332831F-EFBB-44BC-81D5-A614453A4012Q33634866-7E8019DA-485B-44D5-BA7B-7025B7722D9DQ33670907-5E4CDCC2-58C1-4F27-8C80-3030175A4409Q33670940-8C1EF67F-A633-416B-B7C9-A92C70C72A6FQ33702072-A5F3A3A9-4D61-4AE1-80B4-540FE453BCBBQ33911894-9558216F-8B60-409C-B750-DA9F986D48B6Q33958206-4648B2B6-3714-4008-BDE9-A85166EE3CADQ33990246-94FA277B-761A-4BAF-B423-AABFBBB105B4Q34028864-B5B57269-817A-44A1-ABA1-5FF71F17ED30Q34049754-6450D915-0E3A-4BB5-AF2D-E1C88AF8BC60Q34104172-0F561A44-6203-4FB3-963E-2A14FDA78A3B
P2860
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Treatment with interferon beta ...... clinically isolated syndromes.
@en
Treatment with interferon beta ...... clinically isolated syndromes.
@nl
type
label
Treatment with interferon beta ...... clinically isolated syndromes.
@en
Treatment with interferon beta ...... clinically isolated syndromes.
@nl
prefLabel
Treatment with interferon beta ...... clinically isolated syndromes.
@en
Treatment with interferon beta ...... clinically isolated syndromes.
@nl
P2093
P1433
P1476
Treatment with interferon beta ...... clinically isolated syndromes.
@en
P2093
C H Polman
D H Miller
H P Hartung
M S Freedman
P304
P356
10.1212/01.WNL.0000237641.33768.8D
P407
P577
2006-08-16T00:00:00Z